Peginterferon antiviral treatment after liver cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 65 years old
- Have liver cancer removed with radical surgery or radiofrequency ablation, with complete remission confirmed within 4 weeks
- Have hepatitis B (HBsAg positive)
- Doctor says you can take peginterferon and a nucleoside/nucleotide antiviral medicine
- Agree to sign informed consent and follow study visit/medication rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication (pegylated interferon alfa-2b) for people with hepatitis B-related liver cancer that has been completely removed by surgery or ablation. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study looks at whether giving antiviral medicine after liver cancer treatment helps prevent the cancer from coming back and improves overall outcomes. It is for people with hepatitis B who have had their liver cancer removed or destroyed with a procedure.
This study tests a drug called peginterferon alfa-2b for people with advanced liver cancer that cannot be removed by surgery and who also have hepatitis B. The drug aims to boost the immune system to fight the cancer and may help control the disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.